New real-world data shows significantly improved prophylactic effectiveness in patients treated with Elocta compared with standard half-life factor VIII
New real-world data shows significantly improved prophylactic effectiveness in patients treated with Elocta compared with standard half-life factor VIII Annualised bleed rate (ABR), injection frequency and factor consumption were significantly lower compared to standard half-life (SHL) FVIII prophylaxis Results demonstrated the superior prophylactic effectiveness profile of Elocta vs SHL FVIII when used in a real-world setting A-SURE is the largest prospective, non-interventional study on the effect of extended half-life factors in haemophilia A, and directly